Bain Capital Life Sciences Investors’s Nautilus Biotechnolgy NAUT Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio NAUT Stock Details NAUT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,072,421	Closed	-$923K	–	24
2025 Q1	$923K	Sell	1,072,421 -686,579	-39%	-$1.02M	0.14%	23
2024 Q4	$2.96M	Sell	1,759,000 -241,000	-12%	-$576K	0.35%	22
2024 Q3	$5.7M	Hold	2,000,000	–	–	0.59%	20
2024 Q2	$4.68M	Hold	2,000,000	–	–	0.51%	20
2024 Q1	$5.88M	Hold	2,000,000	–	–	0.47%	23
2023 Q4	$5.98M	Hold	2,000,000	–	–	0.57%	23
2023 Q3	$6.32M	Hold	2,000,000	–	–	0.71%	25
2023 Q2	$7.74M	Hold	2,000,000	–	–	0.8%	24
2023 Q1	$5.54M	Hold	2,000,000	–	–	0.69%	28
2022 Q4	$3.6M	Hold	2,000,000	–	–	0.4%	29
2022 Q3	$4.24M	Hold	2,000,000	–	–	0.51%	29
2022 Q2	$5.38M	Hold	2,000,000	–	–	0.63%	27
2022 Q1	$8.68M	Hold	2,000,000	–	–	0.84%	24
2021 Q4	$10.4M	Hold	2,000,000	–	–	0.82%	23
2021 Q3	$12.3M	Hold	2,000,000	–	–	0.76%	22
2021 Q2	$20.2M	Buy	2,000,000 +1,000,000	+100%	+$10.8M	1.32%	17
2021 Q1	$13.8M	Hold	1,000,000	–	–	0.78%	22
2020 Q4	$10.8M	Hold	1,000,000	–	–	0.68%	19
2020 Q3	$10.8M	Buy	+1,000,000	New	+$10.7M	1.01%	19

Other funds holding NAUT

ACM

AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Cercano Management Bellevue, Washington $2.32B AUM 30.12% 1-Year Est. Return

MVG

Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CFM

Comprehensive Financial Management Los Gatos, California $3.01B AUM 2.93% 1-Year Est. Return

ACI

Amazon.com Inc Seattle, Washington $4.42B AUM 22.6% 1-Year Est. Return

CGL

Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

Bain Capital Life Sciences Investors's NAUT Position: Q2 2025 in Review

Bain Capital Life Sciences Investors sold out of Nautilus Biotechnolgy (NAUT) in Q2 2025, closing a stake of 1,072,421 shares — an estimated $923K sold.

Bain Capital Life Sciences Investors first reported a position in NAUT in Q3 2020 and held it in 19 quarters. The position peaked at $20.2M in Q2 2021. 71 funds tracked by Wall St. Rank hold NAUT as of Q2 2025.

Bain Capital Life Sciences Investors reported no remaining Nautilus Biotechnolgy position as of Q2 2025 after selling out during the quarter.
Bain Capital Life Sciences Investors sold 1,072,421 Nautilus Biotechnolgy shares in Q2 2025, an estimated $923K.
Bain Capital Life Sciences Investors first reported a position in Nautilus Biotechnolgy in Q3 2020 and held it in 19 quarters.
Bain Capital Life Sciences Investors's Nautilus Biotechnolgy position peaked at $20.2M in Q2 2021.
71 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2025.

Based on Bain Capital Life Sciences Investors's 13F filing for Q2 2025, filed 14 Aug 2025.